Mannitol in the assessment of bronchial responsiveness in airway disease

甘露醇评估气道疾病的支气管反应性

基本信息

  • 批准号:
    nhmrc : 245502
  • 负责人:
  • 金额:
    $ 24.35万
  • 依托单位:
  • 依托单位国家:
    澳大利亚
  • 项目类别:
    NHMRC Project Grants
  • 财政年份:
    2003
  • 资助国家:
    澳大利亚
  • 起止时间:
    2003-01-01 至 2005-12-31
  • 项目状态:
    已结题

项目摘要

The airways of people with asthma respond by narrowing too easily and too much to a wide range of stimuli. The tests most commonly used to measure airway responsiveness in asthma are the pharmacological agents methacholine and histamine. When inhaled, they act directly on bronchial muscle causing it to contract and hence the airways to narrow. We have developed a non-pharmacological test using a dry powder of a sugar - mannitol. When inhaled, mannitol causes narrowing of the airways in asthmatics but little or no effect in healthy subjects. Many asthmatics respond to mannitol even when they have few symptoms of asthma. Mannitol causes the airways to narrow 'indirectly' by causing the release of substances from inflammatory cells in the airways (e.g. histamine, leukotrienes and prostaglandins) that cause the muscle to contract. After the inflammation has cleared, either by treatment with inhaled steroids or spontaneously, the response to mannitol is close to healthy subjects. Thus the response to mannitol depends on the presence of inflammation and loss of responsiveness means resolution of inflammation. The significance of this is that the mannitol test may be used as an 'inflammometer'. It would be important if airway responsiveness to mannitol could be used to identify individuals with airway diseases other than asthma, (chronic bronchitis, and chronic obstructive lung disease) who could benefit from treatment with inhaled steroids. This would be significant as there is currently no test to identify those individuals and there are unwanted effects from using steroids. Further, it may be possible to use mannitol to identify individuals with other inflammatory diseases who may be at risk of developing asthma. Some people with asthma, chronic bronchitis and chronic obstructive lung disease have increased levels of oxidative stress. We wish to identify those people and to measure change after treatment with steroids.
哮喘患者的气道对各种刺激的反应是太容易和太多地变窄。最常用于测量哮喘气道反应性的试验是药物乙酰甲胆碱和组胺。当吸入时,它们直接作用于支气管肌肉,导致其收缩,从而使气道变窄。我们开发了一种非药理学试验,使用糖-甘露醇的干粉。当吸入甘露醇时,会导致哮喘患者的气道变窄,但对健康受试者影响很小或没有影响。许多哮喘患者对甘露醇有反应,即使他们几乎没有哮喘症状。甘露醇通过引起气道中的炎症细胞释放物质(例如组胺、白三烯和肾上腺素),导致肌肉收缩,从而“间接”导致气道变窄。在炎症清除后,无论是通过吸入类固醇治疗还是自发治疗,对甘露醇的反应接近健康受试者。因此,对甘露醇的反应取决于炎症的存在,反应性的丧失意味着炎症的消退。这一点的意义在于甘露醇试验可用作“炎症测定仪”。如果气道对甘露醇的反应性可用于识别哮喘以外的气道疾病(慢性支气管炎和慢性阻塞性肺病)患者,这些患者可从吸入性类固醇治疗中获益,这将是非常重要的。这将是重要的,因为目前没有测试来识别这些个体,并且使用类固醇会产生不必要的影响。此外,可能使用甘露醇来识别患有其他炎性疾病的个体,这些个体可能有患哮喘的风险。一些患有哮喘、慢性支气管炎和慢性阻塞性肺病的人氧化应激水平增加。我们希望识别这些人并测量类固醇治疗后的变化。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Prof John Seale其他文献

Prof John Seale的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

相似国自然基金

基于重要农地保护LESA(Land Evaluation and Site Assessment)体系思想的高标准基本农田建设研究
  • 批准号:
    41340011
  • 批准年份:
    2013
  • 资助金额:
    20.0 万元
  • 项目类别:
    专项基金项目
城镇居民亚健康状态的评价方法学及健康管理模式研究
  • 批准号:
    81172775
  • 批准年份:
    2011
  • 资助金额:
    14.0 万元
  • 项目类别:
    面上项目

相似海外基金

An Inhaled Microbiome-Targeted Biotherapeutic for Treatment of COPD
一种吸入性微生物组靶向生物治疗药物,用于治疗慢性阻塞性肺病
  • 批准号:
    10600887
  • 财政年份:
    2023
  • 资助金额:
    $ 24.35万
  • 项目类别:
An Inhaled Microbiome-Targeted Biotherapeutic for Treatment of COPD
一种吸入性微生物组靶向生物治疗药物,用于治疗慢性阻塞性肺病
  • 批准号:
    10917559
  • 财政年份:
    2023
  • 资助金额:
    $ 24.35万
  • 项目类别:
Project 3 - Lung Health and Inflammation
项目 3 - 肺部健康与炎症
  • 批准号:
    10628253
  • 财政年份:
    2023
  • 资助金额:
    $ 24.35万
  • 项目类别:
Respiratory health effects of aerosolized delta-8-THC and its oxidation products
雾化 delta-8-THC 及其氧化产物对呼吸系统健康的影响
  • 批准号:
    10752031
  • 财政年份:
    2023
  • 资助金额:
    $ 24.35万
  • 项目类别:
Super-Resolution Imaging of Higher-Order Heterochromatin Structure for Early Detection of Lung Carcinogenesis
高阶异染色质结构的超分辨率成像用于早期检测肺癌
  • 批准号:
    10592368
  • 财政年份:
    2022
  • 资助金额:
    $ 24.35万
  • 项目类别:
Project 2
项目2
  • 批准号:
    10349752
  • 财政年份:
    2022
  • 资助金额:
    $ 24.35万
  • 项目类别:
Impact of quercetin on inflammatory and oxidative stress markers in COPD
槲皮素对慢性阻塞性肺病炎症和氧化应激标志物的影响
  • 批准号:
    10701080
  • 财政年份:
    2022
  • 资助金额:
    $ 24.35万
  • 项目类别:
Airway Biomarker Based Assessment of Combusted to Non-Combusted Tobacco Use Transition Effects
基于气道生物标志物的燃烧型烟草向非燃烧型烟草使用过渡效果的评估
  • 批准号:
    10506004
  • 财政年份:
    2022
  • 资助金额:
    $ 24.35万
  • 项目类别:
Project 2
项目2
  • 批准号:
    10707440
  • 财政年份:
    2022
  • 资助金额:
    $ 24.35万
  • 项目类别:
Assessing the Pulmonary Toxicity of Microplastic Fibers Complexed with Azo Dyes
评估与偶氮染料复合的微塑料纤维的肺部毒性
  • 批准号:
    10593414
  • 财政年份:
    2022
  • 资助金额:
    $ 24.35万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了